title: Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia.
abstract: Graft rejection has been a problem after marrow grafts for patients with aplastic anemia who were conditioned with cyclophosphamide (CY). Rejection lessened when patients were given the marrow donor's peripheral blood buffy-coat cells in addition to the marrow, but this result was achieved at the price of more chronic graft-versus-host disease (GVHD). Results with second transplants suggested that CY alternating with antithymocyte globulin (ATG) was more immunosuppressive than CY alone. Therefore, the current study explored CY and ATG without buffy-coat cell transfusions in 39 patients with aplastic anemia given marrow transplants from HLA-identical family members (siblings in 38 cases, father in 1 case). We hoped both to minimize the risks of graft rejection and of chronic GVHD and to improve survival. Patients were 2 to 52 years of age (median, 24.5); 87% had received previous transfusions, and 41% had therapy with immunosuppressive agents before transplant. They were administered four daily doses of CY (total, 200 mg/kg) alternating with three doses of ATG (total, 90 mg/kg) followed by an HLA-identical marrow graft. Methotrexate and cyclosporine were administered to prevent GVHD. Two patients rejected their grafts (5%), and both were successfully retransplanted. Acute (grade 2 or 3) GVHD occurred in 15% and chronic GVHD in 34% of patients. The actuarial survival rate at 3 years was 92%, which compares favorably to the 72% survival rate in 39 historical patients who were matched with current patients for age and risk factors for rejection and GVHD. CY/ATG is a well-tolerated and effective conditioning program for marrow grafting in aplastic anemia that, when combined with GVHD prevention by methotrexate/cyclosporine, results in excellent survival.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA 98104-2092.
authors.forename: R
authors.initials: R
authors.lastname: Storb
authors.forename: R
authors.initials: R
authors.lastname: Etzioni
authors.forename: C
authors.initials: C
authors.lastname: Anasetti
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.forename: C D
authors.initials: CD
authors.lastname: Buckner
authors.forename: W
authors.initials: W
authors.lastname: Bensinger
authors.forename: E
authors.initials: E
authors.lastname: Bryant
authors.forename: R
authors.initials: R
authors.lastname: Clift
authors.forename: H J
authors.initials: HJ
authors.lastname: Deeg
authors.forename: K
authors.initials: K
authors.lastname: Doney
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000601:surgery*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000379:methods*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000150:complications; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D008297:Male; D016019:Survival Analysis
chemical_list: D000961:Antilymphocyte Serum; D003520:Cyclophosphamide